...
首页> 外文期刊>The Journal of Experomental Medicine >Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells.
【24h】

Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells.

机译:产生人-人杂交瘤的抗体。二。对人白血病细胞具有特异性的抗体的衍生和表征。

获取原文
           

摘要

Human-human hybridoma technology was used to immortalize human B lymphocytes from patients with acute myeloid leukemia (AML) to study the antigenic repertoire of the humoral immune response against the patients' own leukemia cells and against leukemic cells from other patients. Nine fusions were done with lymphocytes from seven AML patients, and all with the human RH-L4 B lymphoma line as malignant fusion partner. A total of 305 Ig-producing hybrids were obtained. 26 reacted with cell surface components on AML cells, but 21 were found not to be specific for leukemia cells, when screened for reactivity against a panel of normal and malignant cells of both human and murine origin. Five hybridomas secreted Ig with high specificity for human leukemia cells, but only one hybridoma culture, aml-18, was stable in respect to Ig-production and growth upon repeated clonings and expansion in liquid cultures. A method was developed to grow human hybridomas as ascites tumors in nude mice, but the ascites fluid did not contain increased amount of antibody. The reactivity of the aml-18 antibody (gamma, kappa) was analyzed against samples of mononuclear cells from peripheral blood of 63 patients with leukemia and with cytologically verified leukemia cells in the blood. 22 of 54 AML samples reacted with aml-18. The reactivity pattern was not correlated to any categories of the French-American-British (FAB) classification; two of four ALL were positive. Moreover, a pronounced intratumoral antigenic heterogeneity in regard to aml-18 reactivity was seen and indicates a high degree of diversity in the immunological phenotype within individual AML cell populations. The study demonstrates that some patients with AML generate an immune response against their autologous malignant cells, and that the antigenic determinant in the case of aml-18 is also expressed specifically on leukemic cells from other patients.
机译:人类-人类杂交瘤技术用于使来自急性髓细胞性白血病(AML)患者的人B淋巴细胞永生化,以研究针对患者自身白血病细胞和其他患者白血病细胞的体液免疫应答的抗原库。用来自7名AML患者的淋巴细胞进行了9次融合,所有融合均以人RH-L4 B淋巴瘤系为恶性融合伴侣。总共获得了305个产生Ig的杂种。 26个细胞与AML细胞上的细胞表面成分发生了反应,但在筛选与人和鼠源性正常细胞和恶性细胞的反应性时,发现21个细胞对白血病细胞不是特异性的。五种杂交瘤细胞分泌出对人白血病细胞具有高特异性的Ig,但是在反复克隆和在液体培养物中扩增后,只有一种杂交瘤培养物aml-18在Ig的产生和生长方面是稳定的。开发了一种在裸鼠中将人类杂交瘤作为腹水肿瘤生长的方法,但是腹水中抗体的含量没有增加。分析了aml-18抗体(γ,κ)与63例白血病患者外周血中单核细胞样品以及血液中经细胞学验证的白血病细胞的反应性。 54个AML样品中有22个与aml-18反应。反应模式与法国-美国-英国(FAB)分类的任何类别均无关。四分之二的ALL均为阳性。此外,观察到关于aml-18反应性的明显的肿瘤内抗原异质性,表明在单个AML细胞群体中免疫表型的高度多样性。该研究表明,某些AML患者对自身的恶性肿瘤细胞产生免疫应答,而aml-18的抗原决定簇在其他患者的白血病细胞上也有特异性表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号